A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary. Up to 30% of patients with hepatitis C virus (HCV) infection and normal serum alanine aminotransferase (NALT) have significant liver disease. Currently, many of these patients undergo a liver biopsy to guide therapeutic decisions. The BreathID® continuous online 13 C‐methacetin breath test (MBT) reflects hepatic microsomal function and correlates with hepatic fibrosis. To assess its role in identifying intrahepatic inflammation and fibrosis in NALT patients, we tested 100 patients with untreated chronic HCV infection, and 100 age‐ and sex‐matched healthy volunteers using 13 C MBT following ingestion of 75 mg methacetin. All HCV patients had undergone a liver biopsy within 12 months of performing the MBT. Patients with a necroinflammatory grade ≤4 or >4, based on Ishak (modified HAI) score, HAIa + HAIb + HAIc + HAId, were defined as having low or high inflammation, respectively. Patients with a histological activity fibrosis stage ≤2 or >2, were defined as having nonsignificant or significant fibrosis, respectively. A proprietary algorithm to differentiate intrahepatic inflammation within chronic HCV patients with NALT achieved an area under the curve (AUC) of 0.90. Setting a threshold on the point of best agreement (at 83%) results in 82% sensitivity and 84% specificity. With application of another proprietary algorithm to differentiate patients with nonsignificant or significant fibrosis, 67% of liver biopsies performed in the patient group could have been avoided. This algorithm achieved an AUC of 0.92, with a sensitivity of 91% and a specificity of 88%. There was no correlation between body mass index (BMI) and MBT scores for patients with the same histological score. The continuous BreathID®13 C MBT is an accurate tool for measuring the degree of inflammation and fibrosis in patients with chronic HCV infection and NALT. As such, it may prove to be a powerful, noninvasive alternative to liver biopsy in the management of this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Cited by
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
“Functional studies currently under evaluation include a cholate clearance test which has been extensively validated in HCV patients [75] as well as a breath test that assesses the ability of microsomal enzymes to metabolize a (13)C labeled orally administered substrate to release (13)CO2 in the nasal breath [76].”
BackgroundNon-Invasive markers for hepatic fibrosis
Baranova, A., Lal, P., Birerdinc, A., & Younossi, Z. M. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-91 · Cited by 297
LOXL2—A New Target in Antifibrogenic Therapy?
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071634 · Cited by 79
Role of Liver Biopsy in the Era of Direct-Acting Antivirals
Gonzalez, H. C., Jafri, S. M., & Gordon, S. C. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0307-z · Cited by 25
“Methacetin BT [45] I3: 0.”
Background
Metadata
- Authors
- Lalazar, G., Pappo, O., Hershcovici, T., Hadjaj, T., Shubi, M., Ohana, H., Hemed, N., & Ilan, Y.
- Venue
- Journal of Viral Hepatitis
- Publisher
- Wiley
- Published
- 2008-09-19
- Volume
- 15
- Issue
- 10
- Pages
- 716-728
- ISSN
- 1352-0504 (ISSN-L)
- 1365-2893
- OpenAlex
- W2050208530
- Cited by
- 53
- References
- 1
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. https://app.cochat.ai/papers/10.1111/j.1365-2893.2008.01007.x
- The paper
- Lalazar, G., Pappo, O., Hershcovici, T., Hadjaj, T., Shubi, M., Ohana, H., Hemed, N., & Ilan, Y. (2008). A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. Journal of Viral Hepatitis. https://doi.org/10.1111/j.1365-2893.2008.01007.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.